Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors from the central nervous method, conolidine modulates alternate molecular targets. A Science Improvements review located that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabil... https://ferdinandn875prw7.blogvivi.com/profile